Shots:

• PhoreMost to receive upfront and research funding plus milestones and will utilize its expertise and phenotypic screening platform- SITESEEKER for the targets identified by BI and will be further included in and validated in BI’s pipeline
• The focus of the agreement is to enhance BI’s drug discovery pipeline utilizing PhoreMost’s PROTEINi and SITESEEKER platform to identify novel targets for multiple diseases
• SITESEEKER platform is based on PROTEINi technology enables the inception of novel drug discovery programs. PROTEINi are small fragments of larger proteins broken into small subunits retaining a 3D structure find a diversity of new 3D binding sites across the entire proteome

Click here to read full press release/ article | Ref: GlobeNewswire | Image: Behance